Y-Intercept (HK)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Y-Intercept (HK)’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,829	Closed	-$208K	–	1668
2022 Q4	$208K	Buy	+1,829	New	+$152K	0.03%	819
2022 Q3	–	Sell	-28,475	Closed	-$2.27M	–	1384
2022 Q2	$2.27M	Buy	28,475 +21,824	+328%	+$2.07M	0.3%	73
2022 Q1	$700K	Buy	+6,651	New	+$648K	0.16%	184
2021 Q4	–	Sell	-5,018	Closed	-$550K	–	964
2021 Q3	$550K	Sell	5,018 -9,293	-65%	-$965K	0.1%	311
2021 Q2	$1.34M	Buy	14,311 +10,832	+311%	+$997K	0.34%	52
2021 Q1	$303K	Buy	+3,479	New	+$294K	0.08%	399

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Y-Intercept (HK)'s HZNP Position: Q1 2023 in Review

Y-Intercept (HK) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 1,829 shares — an estimated $208K sold.

Y-Intercept (HK) first reported a position in HZNP in Q1 2021 and held it in 6 quarters. The position peaked at $2.27M in Q2 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Y-Intercept (HK) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Y-Intercept (HK) sold 1,829 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $208K.
Y-Intercept (HK) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 6 quarters.
Y-Intercept (HK)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.27M in Q2 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Y-Intercept (HK)'s 13F filing for Q1 2023, filed 9 May 2023.